Back to search
FDAFDA · Food and drugs·Recall number D-0535-2025

Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01

Published July 30, 2025 · Recall initiated: July 9, 2025

Summary

FDA records drug Class II recall D-0535-2025, published July 30, 2025 and initiated July 9, 2025. Recalling firm: Imprimis NJOF, LLC; Status: Completed; Reported quantity: 6,880 vials; Lot: Lot: 24DEC017, Exp. 07/12/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Sub-Potent Drug: Subpotent assay results during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
Nationwide in the USA
Lot
Lot: 24DEC017, Exp. 07/12/2025.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01 recalled?

Yes. FDA published recall D-0535-2025 on July 30, 2025. Reported hazard: Sub-Potent Drug: Subpotent assay results during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter